



NAPLEX Advantage Summary Report

State University School College of Pharmacy

Prepared by NABP
April 3, 2025

State University School College of Pharmacy

Background

This report describes the NAPLEX Advantage™ results for 160 of your students who received a scaled score. Any of your students that did not receive a scaled score are not included in this report.

All students with a valid exam result are included in any values reported for your state and for the nation for the current examination academic year.

The NAPLEX Advantage is designed to be similar to the North American Pharmacist Licensure Examination® (NAPLEX®) in administration method, content, and scoring. Therefore, the NAPLEX Advantage may provide insight into future performance on the NAPLEX.

For all state- and national-level data reported, your school's data is included in those aggregate totals. If your school is the only school who has tested in your state, your school's data and your state's data will be the same.

Results for Overall Scaled Scores

NAPLEX Advantage scaled scores are based on the same scale that is used to calculate NAPLEX scaled scores. On the NAPLEX, a scaled score of 75 or greater represents a passing score. [Table 1](#) provides a summary of scaled scores for your students, your state, and students nationally.

Table 1: Average Scaled Scores by Student Location

| Location | Total Scored Exams | Average Scaled Score | Scaled Score SD (Min, Max) | Number (Percent) of Scaled Scores At or Above 75 |
|----------------|--------------------|----------------------|----------------------------|--|
| Your School | 160 | 69.93 | 22.81 (15, 130) | 67 (41.9%) |
| Your State: XX | 630 | 68.87 | 21.81 (5, 130) | 264 (41.9%) |
| National | 3000 | 69.08 | 20.97 (5, 131) | 1226 (40.9%) |

Note: SD means standard deviation. A minimum number of two exams are needed for an SD to be calculated.

Table 2 breaks down the average scaled score for your students, your state, and students nationally by their expected graduation year.

Table 2: Average Scaled Scores by Student Location and Expected Graduation Year

| Location | Expected Graduation Year | Total Scored Exams | Average Scaled Score | Scaled Score SD (Min, Max) | Number (Percent) of Scaled Scores At or Above 75 |
|----------------|--------------------------|--------------------|----------------------|----------------------------|--|
| Your School | 2028 | 5 | 51.00 | 25.73 (24, 90) | 1 (20.0%) |
| | 2027 | 19 | 62.42 | 22.05 (24, 101) | 6 (31.6%) |
| | 2026 | 58 | 69.48 | 20.68 (34, 122) | 22 (37.9%) |
| | 2025 | 78 | 73.31 | 23.69 (15, 130) | 38 (48.7%) |
| Your State: XX | 2028 | 24 | 53.25 | 26.02 (6, 106) | 4 (16.7%) |
| | 2027 | 70 | 60.01 | 21.57 (5, 101) | 21 (30.0%) |
| | 2026 | 226 | 68.15 | 19.68 (13, 123) | 88 (38.9%) |
| | 2025 | 310 | 72.59 | 21.93 (15, 130) | 151 (48.7%) |
| National | 2028 | 128 | 59.08 | 19.75 (6, 106) | 28 (21.9%) |
| | 2027 | 304 | 61.72 | 20.29 (5, 105) | 90 (29.6%) |
| | 2026 | 1068 | 66.37 | 19.95 (10, 126) | 377 (35.3%) |
| | 2025 | 1500 | 73.36 | 20.91 (15, 131) | 731 (48.7%) |

Note: SD means standard deviation. A minimum number of two exams are needed for an SD to be calculated.

Distribution of Scaled Scores

Figure 1 displays the distribution of your students' scaled scores. The vertical red line indicates a scaled score of 75, which is required to meet the NAPLEX passing standard, and the remaining lines show the distribution of scores for students by their location. A taller line indicates more students at that specific scaled score, and the heights at the scaled scores to the right of the vertical red line show the number of students with a scaled score at or above the NAPLEX passing standard.

Figure 1: Distribution of Your Examinees' Scaled Scores (NAPLEX® Passing Standard Represented by Solid Red Line)





Figure 2 displays the distribution of your students' scaled scores by expected graduation year. The vertical red line indicates a scaled score of 75, which is required to meet the NAPLEX passing standard, and the remaining lines show the distribution of scores for students by their location and expected graduation year. A taller line indicates more students at that specific scaled score, and the heights at the scaled scores to the right of the vertical red line show the number of students with a scaled score at or above the NAPLEX passing standard.

Figure 2: Distribution of Your Examinees' Scaled Scores by Expected Graduation Year (NAPLEX® Passing Standard Represented by Solid Red Line)



Results for Content Domain Scaled Scores

The NAPLEX content domains, their descriptions, and the approximate percent of exam questions classified to each area are provided in [Table 3](#). For further details on the content domains, please refer to <https://nabp.pharmacy/wp-content/uploads/2024/09/NAPLEX-Content-Outline.pdf>.

Table 3: Content Domain Descriptions and Exam Weights

| Content Domain | Description | Approximate Percent of Exam |
|----------------|---|-----------------------------|
| Domain 1 | Foundational Knowledge for Pharmacy Practice | 25% |
| Domain 2 | Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) | 25% |
| Domain 3 | Person-Centered Assessment and Treatment Planning | 40% |
| Domain 4 | Professional Practice | 5% |
| Domain 5 | Pharmacy Management and Leadership | 5% |

Average Scaled Score Per Content Domain

[Table 4](#) shows the average scaled score in each of the five content domains for students from your school, your state, and the nation.

Table 4: Average Scaled Scores for Each Content Domain for Your School, Your State, and the Nation

| Location | Domain 1 Average Scaled Score | Domain 2 Average Scaled Score | Domain 3 Average Scaled Score | Domain 4 Average Scaled Score | Domain 5 Average Scaled Score |
|----------------|--|--|--|--|--|
| Your School | 53.0 | 54.4 | 51.2 | 54.0 | 53.5 |
| Your State: XX | 53.7 | 54.0 | 53.0 | 54.6 | 53.9 |
| National | 54.2 | 54.5 | 54.1 | 54.6 | 54.2 |

Figure 3 displays the average scaled scores, the upper and lower quartiles of the scores, and the values of scores lying outside the interquartile ranges for each content domain for students from your school, your state, and the nation.

Figure 3: Distribution of Scaled Scores by Content Domain for Your School, Your State, and National Students





Table 5 shows the average scaled score in each of the five content domains for students from your school, your state, and the nation, broken down by expected graduation year.

Table 5: Average Scaled Scores for Each Content Domain for Your School, Your State, and the Nation by Expected Graduation Year

| Location | Expected Graduation Year | Domain 1 Average Scaled Score | Domain 2 Average Scaled Score | Domain 3 Average Scaled Score | Domain 4 Average Scaled Score | Domain 5 Average Scaled Score |
|----------------|--------------------------|--|--|--|--|--|
| Your School | 2028 | 38.4 | 55.6 | 46.6 | 38.8 | 47.4 |
| | 2027 | 54.3 | 45.2 | 38.9 | 44.3 | 47.2 |
| | 2026 | 49.2 | 54.7 | 50.9 | 51.3 | 52.6 |
| | 2025 | 56.4 | 56.3 | 54.7 | 59.4 | 56.0 |
| Your State: XX | 2028 | 38.0 | 42.5 | 44.1 | 41.3 | 44.8 |
| | 2027 | 49.7 | 45.6 | 44.9 | 45.3 | 45.4 |
| | 2026 | 52.8 | 53.6 | 50.6 | 51.9 | 52.7 |
| | 2025 | 56.5 | 57.1 | 57.2 | 59.6 | 57.3 |
| National | 2028 | 43.6 | 43.1 | 43.0 | 44.5 | 39.8 |
| | 2027 | 47.8 | 49.2 | 45.1 | 47.5 | 47.6 |
| | 2026 | 52.9 | 52.5 | 53.1 | 52.2 | 52.2 |
| | 2025 | 57.2 | 58.0 | 57.6 | 58.6 | 58.1 |

Figure 4 displays the average scaled scores, the upper and lower quartiles of the scores, and the values of scores lying outside the interquartile ranges for each content domain for students from your school, your state, and the nation, grouped by students' expected graduation year.

Figure 4: Distribution of Scaled Scores by Content Domain and Expected Graduation Year for Your School, Your State, and National Students



Content Domain PLD Results

The tables in this section provide data related to students' performance levels in each content domain. The four Performance Level Descriptor (PLD) categories are detailed below.

- **Level 1:** Performance at this level is **far below meeting the minimum performance** necessary to demonstrate competency.
- **Level 2:** Performance at this level **does NOT meet the minimum performance** necessary to demonstrate competency.
- **Level 3:** Performance at this level **meets the minimum performance** necessary to demonstrate competency.
- **Level 4:** Performance at this level **exceeds the minimum performance** necessary to demonstrate competency.

Table 6 shows the number and percentage of students in each content domain that achieved each PLD level. These are shown for students in your school, your state, and the nation.

Table 6: Content Domain PLDs by Location

| Location | Content Domain | Performance Level Descriptor | | | | Total |
|----------------|----------------|------------------------------|--------------|------------|-------------|-------|
| | | 1 - Far Below | 2 - Below | 3 - Meets | 4 - Exceeds | |
| Your School | 1 | 68 (42.5%) | 73 (45.6%) | 19 (11.9%) | 0 (0.0%) | 160 |
| | 2 | 54 (33.8%) | 94 (58.8%) | 12 (7.5%) | 0 (0.0%) | 160 |
| | 3 | 66 (41.2%) | 83 (51.9%) | 10 (6.2%) | 1 (0.6%) | 160 |
| | 4 | 60 (37.5%) | 88 (55.0%) | 12 (7.5%) | 0 (0.0%) | 160 |
| | 5 | 66 (41.2%) | 80 (50.0%) | 13 (8.1%) | 1 (0.6%) | 160 |
| Your State: XX | 1 | 240 (38.1%) | 334 (53.0%) | 55 (8.7%) | 1 (0.2%) | 630 |
| | 2 | 230 (36.5%) | 353 (56.0%) | 44 (7.0%) | 3 (0.5%) | 630 |
| | 3 | 248 (39.4%) | 333 (52.9%) | 47 (7.5%) | 2 (0.3%) | 630 |
| | 4 | 238 (37.8%) | 336 (53.3%) | 55 (8.7%) | 1 (0.2%) | 630 |
| | 5 | 245 (38.9%) | 329 (52.2%) | 52 (8.3%) | 4 (0.6%) | 630 |
| National | 1 | 1103 (36.8%) | 1619 (54.0%) | 272 (9.1%) | 6 (0.2%) | 3000 |
| | 2 | 1069 (35.6%) | 1678 (55.9%) | 242 (8.1%) | 11 (0.4%) | 3000 |
| | 3 | 1108 (36.9%) | 1624 (54.1%) | 261 (8.7%) | 7 (0.2%) | 3000 |
| | 4 | 1126 (37.5%) | 1573 (52.4%) | 291 (9.7%) | 10 (0.3%) | 3000 |
| | 5 | 1144 (38.1%) | 1572 (52.4%) | 276 (9.2%) | 8 (0.3%) | 3000 |

Table 7 shows the number and percentage of students in each content domain that achieved each PLD level by expected graduation year. These are shown for students in your school, your state, and the nation.

Table 7: Content Domain PLDs by Location and Expected Graduation Year

| Location | Graduation Year | Content Domain | Performance Level Descriptor | | | | Total |
|----------------|-----------------|----------------|------------------------------|-------------|------------|-------------|-------|
| | | | 1 - Far Below | 2 - Below | 3 - Meets | 4 - Exceeds | |
| Your School | 2028 | 1 | 4 (80.0%) | 1 (20.0%) | 0 (0.0%) | 0 (0.0%) | 5 |
| | | 2 | 3 (60.0%) | 2 (40.0%) | 0 (0.0%) | 0 (0.0%) | 5 |
| | | 3 | 3 (60.0%) | 2 (40.0%) | 0 (0.0%) | 0 (0.0%) | 5 |
| | | 4 | 3 (60.0%) | 2 (40.0%) | 0 (0.0%) | 0 (0.0%) | 5 |
| | | 5 | 3 (60.0%) | 2 (40.0%) | 0 (0.0%) | 0 (0.0%) | 5 |
| | 2027 | 1 | 7 (36.8%) | 10 (52.6%) | 2 (10.5%) | 0 (0.0%) | 19 |
| | | 2 | 11 (57.9%) | 7 (36.8%) | 1 (5.3%) | 0 (0.0%) | 19 |
| | | 3 | 11 (57.9%) | 8 (42.1%) | 0 (0.0%) | 0 (0.0%) | 19 |
| | | 4 | 14 (73.7%) | 5 (26.3%) | 0 (0.0%) | 0 (0.0%) | 19 |
| | | 5 | 10 (52.6%) | 9 (47.4%) | 0 (0.0%) | 0 (0.0%) | 19 |
| | 2026 | 1 | 34 (58.6%) | 21 (36.2%) | 3 (5.2%) | 0 (0.0%) | 58 |
| | | 2 | 15 (25.9%) | 39 (67.2%) | 4 (6.9%) | 0 (0.0%) | 58 |
| | | 3 | 26 (44.8%) | 29 (50.0%) | 3 (5.2%) | 0 (0.0%) | 58 |
| | | 4 | 25 (43.1%) | 30 (51.7%) | 3 (5.2%) | 0 (0.0%) | 58 |
| | | 5 | 26 (44.8%) | 27 (46.6%) | 5 (8.6%) | 0 (0.0%) | 58 |
| | 2025 | 1 | 23 (29.5%) | 41 (52.6%) | 14 (17.9%) | 0 (0.0%) | 78 |
| | | 2 | 25 (32.1%) | 46 (59.0%) | 7 (9.0%) | 0 (0.0%) | 78 |
| | | 3 | 26 (33.3%) | 44 (56.4%) | 7 (9.0%) | 1 (1.3%) | 78 |
| | | 4 | 18 (23.1%) | 51 (65.4%) | 9 (11.5%) | 0 (0.0%) | 78 |
| | | 5 | 27 (34.6%) | 42 (53.8%) | 8 (10.3%) | 1 (1.3%) | 78 |
| Your State: XX | 2028 | 1 | 19 (79.2%) | 4 (16.7%) | 1 (4.2%) | 0 (0.0%) | 24 |
| | | 2 | 16 (66.7%) | 8 (33.3%) | 0 (0.0%) | 0 (0.0%) | 24 |
| | | 3 | 18 (75.0%) | 5 (20.8%) | 1 (4.2%) | 0 (0.0%) | 24 |
| | | 4 | 18 (75.0%) | 6 (25.0%) | 0 (0.0%) | 0 (0.0%) | 24 |
| | | 5 | 15 (62.5%) | 9 (37.5%) | 0 (0.0%) | 0 (0.0%) | 24 |
| | 2027 | 1 | 37 (52.9%) | 28 (40.0%) | 5 (7.1%) | 0 (0.0%) | 70 |
| | | 2 | 43 (61.4%) | 26 (37.1%) | 1 (1.4%) | 0 (0.0%) | 70 |
| | | 3 | 38 (54.3%) | 30 (42.9%) | 2 (2.9%) | 0 (0.0%) | 70 |
| | | 4 | 47 (67.1%) | 21 (30.0%) | 2 (2.9%) | 0 (0.0%) | 70 |
| | | 5 | 43 (61.4%) | 25 (35.7%) | 2 (2.9%) | 0 (0.0%) | 70 |
| | 2026 | 1 | 97 (42.9%) | 117 (51.8%) | 12 (5.3%) | 0 (0.0%) | 226 |
| | | 2 | 81 (35.8%) | 130 (57.5%) | 15 (6.6%) | 0 (0.0%) | 226 |
| | | 3 | 105 (46.5%) | 111 (49.1%) | 10 (4.4%) | 0 (0.0%) | 226 |
| | | 4 | 101 (44.7%) | 114 (50.4%) | 11 (4.9%) | 0 (0.0%) | 226 |
| | | 5 | 91 (40.3%) | 122 (54.0%) | 13 (5.8%) | 0 (0.0%) | 226 |

(continued ...)

Table 7: Content Domain PLDs by Location and Expected Graduation Year (*continued*)

| Location | Graduation Year | Content Domain | 1 - Far Below | 2 - Below | 3 - Meets | 4 - Exceeds | Total |
|----------|-----------------|----------------|---------------|-------------|-------------|-------------|-------|
| National | 2025 | 1 | 87 (28.1%) | 185 (59.7%) | 37 (11.9%) | 1 (0.3%) | 310 |
| | | 2 | 90 (29.0%) | 189 (61.0%) | 28 (9.0%) | 3 (1.0%) | 310 |
| | | 3 | 87 (28.1%) | 187 (60.3%) | 34 (11.0%) | 2 (0.6%) | 310 |
| | | 4 | 72 (23.2%) | 195 (62.9%) | 42 (13.5%) | 1 (0.3%) | 310 |
| | | 5 | 96 (31.0%) | 173 (55.8%) | 37 (11.9%) | 4 (1.3%) | 310 |
| | 2028 | 1 | 90 (70.3%) | 34 (26.6%) | 4 (3.1%) | 0 (0.0%) | 128 |
| | | 2 | 89 (69.5%) | 36 (28.1%) | 3 (2.3%) | 0 (0.0%) | 128 |
| | | 3 | 88 (68.8%) | 37 (28.9%) | 3 (2.3%) | 0 (0.0%) | 128 |
| | | 4 | 79 (61.7%) | 46 (35.9%) | 3 (2.3%) | 0 (0.0%) | 128 |
| | | 5 | 91 (71.1%) | 36 (28.1%) | 1 (0.8%) | 0 (0.0%) | 128 |
| | 2027 | 1 | 169 (55.6%) | 119 (39.1%) | 16 (5.3%) | 0 (0.0%) | 304 |
| | | 2 | 146 (48.0%) | 147 (48.4%) | 11 (3.6%) | 0 (0.0%) | 304 |
| | | 3 | 174 (57.2%) | 124 (40.8%) | 6 (2.0%) | 0 (0.0%) | 304 |
| | | 4 | 172 (56.6%) | 120 (39.5%) | 12 (3.9%) | 0 (0.0%) | 304 |
| | | 5 | 174 (57.2%) | 117 (38.5%) | 13 (4.3%) | 0 (0.0%) | 304 |
| | 2026 | 1 | 424 (39.7%) | 568 (53.2%) | 76 (7.1%) | 0 (0.0%) | 1068 |
| | | 2 | 430 (40.3%) | 582 (54.5%) | 56 (5.2%) | 0 (0.0%) | 1068 |
| | | 3 | 429 (40.2%) | 565 (52.9%) | 74 (6.9%) | 0 (0.0%) | 1068 |
| | | 4 | 479 (44.9%) | 514 (48.1%) | 75 (7.0%) | 0 (0.0%) | 1068 |
| | | 5 | 463 (43.4%) | 545 (51.0%) | 60 (5.6%) | 0 (0.0%) | 1068 |
| | 2025 | 1 | 420 (28.0%) | 898 (59.9%) | 176 (11.7%) | 6 (0.4%) | 1500 |
| | | 2 | 404 (26.9%) | 913 (60.9%) | 172 (11.5%) | 11 (0.7%) | 1500 |
| | | 3 | 417 (27.8%) | 898 (59.9%) | 178 (11.9%) | 7 (0.5%) | 1500 |
| | | 4 | 396 (26.4%) | 893 (59.5%) | 201 (13.4%) | 10 (0.7%) | 1500 |
| | | 5 | 416 (27.7%) | 874 (58.3%) | 202 (13.5%) | 8 (0.5%) | 1500 |

Content Subdomain and Third-Level Results

Each question on the NAPLEX Advantage is classified to a content subdomain or third-level. Some content subdomains or third-levels may not be addressed on an exam, and those subdomains or third-levels that do not have questions classified to them are not included in the tables in this section. In content subdomains or third-levels where there are multiple questions, the proportion reported is cumulative across all questions classified to that subdomain or third-level. These results are reported only as a general indicator of subdomain or third-level performance. Because the level of item difficulty and the number of items vary across subdomains and third-levels, inferences about overall scores should not be made using subdomain or third-level results.

Your School

Table 8 provides the proportion of your students answering questions correctly in each subdomain or third-level.

Table 8: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year

| Subdomain/Third-Level | 2028 | Proportion Correct Expected Graduation Year | | | Overall |
|--|-------|--|-------|-------|---------|
| | | 2027 | 2026 | 2025 | |
| 1. Foundational Knowledge for Pharmacy Practice (~25% of Exam) | | | | | |
| A. Pharmaceutical science principles and concepts | - | - | - | - | - |
| 1. Pharmacology (N = 1) | 0.000 | 0.000 | 0.552 | 0.590 | 0.488 |
| 2. Pharmacokinetics, pharmacodynamics, or pharmacogenomics (N = 1) | 0.000 | 0.000 | 0.397 | 0.462 | 0.369 |
| 3. Pharmaceutics (N = 1) | 0.000 | 0.000 | 0.500 | 0.487 | 0.419 |
| B. Pharmaceutical compounding | - | - | - | - | - |
| 1. Nonsterile preparations (N = 2) | 0.000 | 0.184 | 0.509 | 0.583 | 0.491 |
| 2. Sterile preparations (N = 2) | 0.000 | 0.289 | 0.534 | 0.481 | 0.462 |
| C. Pharmaceutical calculations | - | - | - | - | - |
| 1. Patient parameters or laboratory measures (N = 1) | 0.000 | 0.000 | 0.397 | 0.513 | 0.394 |
| 2. Quantities of drugs to be dispensed or administered (N = 3) | 0.067 | 0.386 | 0.603 | 0.526 | 0.523 |
| 3. Rates of administration (N = 1) | 0.000 | 0.000 | 0.569 | 0.410 | 0.406 |
| 4. Dose conversions (N = 1) | 0.000 | 0.000 | 0.466 | 0.577 | 0.450 |
| 5. Drug concentrations, ratio strengths, osmolarity, or osmolality (N = 1) | 0.000 | 0.000 | 0.431 | 0.449 | 0.375 |

(continued ...)

Table 8: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year
(continued)

| Subdomain/Third-Level | 2028 | 2027 | 2026 | 2025 | Overall |
|--|-------|-------|-------|-------|---------|
| 6. Quantities of drugs or ingredients to be compounded (N = 2) | 0.000 | 0.211 | 0.440 | 0.506 | 0.431 |
| 7. Nutritional needs and the content of nutrient sources (N = 1) | 0.000 | 0.000 | 0.362 | 0.487 | 0.369 |
| 8. Biostatistical, epidemiological, or pharmaco-economic measures (N = 1) | 0.000 | 0.000 | 0.534 | 0.487 | 0.431 |
| 9. Pharmacokinetic parameters (N = 2) | 0.000 | 0.237 | 0.491 | 0.545 | 0.472 |
| D. Drug development processes (eg, clinical trial phases, emergency use authorizations) (N = 1) | 0.000 | 0.000 | 0.500 | 0.500 | 0.425 |
| E. Research design principles and biostatistics (eg, blinding, randomization, biases, statistical tests and outcomes, ethics) (N = 2) | 0.000 | 0.211 | 0.457 | 0.494 | 0.431 |
| F. Retrieval, assessment, and interpretation of primary, secondary, and tertiary resources (N = 2) | 0.000 | 0.184 | 0.466 | 0.449 | 0.409 |
| 2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) (~25% of Exam) | | | | | |
| A. Prescriptions and medication order interpretation | - | - | - | - | - |
| 1. Drug names and therapeutic classes (N = 3) | 0.200 | 0.351 | 0.454 | 0.462 | 0.438 |
| 2. Indications, usage, and dosing regimens (N = 1) | 0.000 | 0.000 | 0.345 | 0.538 | 0.388 |
| 3. Available dosage forms (N = 2) | 0.000 | 0.237 | 0.474 | 0.545 | 0.466 |
| 4. Prescription regulations (eg, boxed warnings, risk evaluation and mitigation strategies) (N = 1) | 0.000 | 0.000 | 0.552 | 0.500 | 0.444 |
| 5. Safety and effectiveness (eg, laboratory parameters, vital signs) (N = 3) | 0.200 | 0.246 | 0.477 | 0.547 | 0.475 |

(continued ...)

Table 8: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year
(continued)

| Subdomain/Third-Level | 2028 | 2027 | 2026 | 2025 | Overall |
|--|-------|-------|-------|-------|---------|
| B. Therapeutic substitutions (eg, formulary restrictions, therapeutic alternatives, shortages, biosimilars) (N = 2) | 0.000 | 0.263 | 0.500 | 0.462 | 0.438 |
| C. Immunization services and documentation | - | - | - | - | - |
| 1. Indications and scheduling (N = 3) | 0.133 | 0.474 | 0.460 | 0.474 | 0.458 |
| 2. Contraindications and precautions (N = 1) | 0.000 | 0.000 | 0.552 | 0.526 | 0.456 |
| 3. Storage and handling (N = 2) | 0.000 | 0.237 | 0.560 | 0.442 | 0.447 |
| 4. Administration (eg, techniques, preparation, routes) (N = 2) | 0.000 | 0.316 | 0.466 | 0.506 | 0.453 |
| 5. Adverse reactions (N = 3) | 0.200 | 0.368 | 0.523 | 0.496 | 0.481 |
| D. Medication handling, storage, stability, and disposal (eg, hazardous and nonhazardous drugs, controlled substances, parenteral medications, sharps handling, temperature control) (N = 2) | 0.000 | 0.211 | 0.569 | 0.474 | 0.462 |
| 3. Person-Centered Assessment and Treatment Planning (~ 40% of Exam) | | | | | |
| A. Medication history, allergy history, and reconciliation (N = 3) | 0.267 | 0.316 | 0.511 | 0.444 | 0.448 |
| B. Health histories, screenings, and assessments (N = 1) | 0.000 | 0.000 | 0.586 | 0.551 | 0.481 |
| C. Patient health conditions, including special populations and medication-related factors | - | - | - | - | - |
| 1. Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology (N = 2) | 0.000 | 0.289 | 0.517 | 0.442 | 0.438 |

(continued...)

Table 8: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year
(continued)

| Subdomain/Third-Level | 2028 | 2027 | 2026 | 2025 | Overall |
|---|-------|-------|-------|-------|---------|
| 2. Appropriateness of therapy (eg, medications, immunizations, nondrug therapy, dosing, contraindications, warnings, evidencebased decision making) (N = 1) | 0.000 | 0.000 | 0.448 | 0.487 | 0.400 |
| 3. Interactions (eg, drug-drug, drug-condition, drug-food, drugallergy, drug-laboratory) (N = 1) | 0.000 | 0.000 | 0.621 | 0.513 | 0.475 |
| 4. Errors and omissions (eg, dosing, duplication, additional therapy needed, unnecessary therapy) (N = 3) | 0.200 | 0.404 | 0.506 | 0.479 | 0.471 |
| 5. Adverse drug reactions (N = 3) | 0.200 | 0.386 | 0.483 | 0.551 | 0.496 |
| 6. Toxicologic exposures and overdoses (N = 2) | 0.000 | 0.289 | 0.457 | 0.532 | 0.459 |
| 7. Adherence (N = 3) | 0.200 | 0.404 | 0.586 | 0.521 | 0.521 |
| D. Therapeutic monitoring, plan development, evaluation, and modifications | - | - | - | - | - |
| 1. Therapeutic goals, clinical endpoints, and follow-up (N = 2) | 0.000 | 0.342 | 0.491 | 0.513 | 0.469 |
| 2. Safety (N = 3) | 0.133 | 0.368 | 0.540 | 0.526 | 0.500 |
| 3. Effectiveness (N = 4) | 0.300 | 0.434 | 0.448 | 0.519 | 0.477 |
| E. Patient education | - | - | - | - | - |
| 1. Lifestyle modifications and health maintenance (N = 1) | 0.000 | 0.000 | 0.638 | 0.615 | 0.531 |
| 2. Medication use, storage, and disposal (N = 3) | 0.200 | 0.351 | 0.494 | 0.504 | 0.473 |
| 3. Disease state management (N = 1) | 0.000 | 0.000 | 0.466 | 0.462 | 0.394 |
| F. Over-the-counter medications and dietary supplements (N = 4) | 0.300 | 0.368 | 0.509 | 0.516 | 0.489 |
| G. Devices to administer medications and self-monitoring tests (N = 3) | 0.200 | 0.298 | 0.546 | 0.440 | 0.454 |

(continued ...)

Table 8: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year
(continued)

| Subdomain/Third-Level | 2028 | 2027 | 2026 | 2025 | Overall |
|--|-------|-------|-------|-------|---------|
| 4. Professional Practice (~5% of Exam) | | | | | |
| A. Adverse drug event reporting and medication error reporting (eg, MedWatch, VAERS) (N = 1) | 0.000 | 0.000 | 0.448 | 0.410 | 0.362 |
| B. Public health initiatives and risk-prevention programs (eg, tobacco and nicotine cessation, antimicrobial stewardship, health screenings, opioid stewardship) (N = 2) | 0.000 | 0.263 | 0.483 | 0.513 | 0.456 |
| C. Social determinants and drivers of health (N = 1) | 0.000 | 0.000 | 0.534 | 0.487 | 0.431 |
| D. Ethical considerations (eg, informed consent, ethical principles, professional conduct and responsibility, patient confidentiality) (N = 1) | 0.000 | 0.000 | 0.534 | 0.526 | 0.450 |
| 5. Pharmacy Management and Leadership (~5% of Exam) | | | | | |
| A. Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety) (N = 1) | 0.000 | 0.000 | 0.552 | 0.577 | 0.481 |
| B. Inventory and supply management (eg, drug recalls, drug shortages) (N = 1) | 0.000 | 0.000 | 0.517 | 0.500 | 0.431 |
| C. Quality improvement activities (eg, medication use evaluation, root-cause analysis, continuous quality improvement) (N = 2) | 0.000 | 0.211 | 0.422 | 0.532 | 0.438 |
| D. Mentorship and preceptorship (eg, providing and receiving feedback, delegation of work activities, preceptor roles) (N = 1) | 0.000 | 0.000 | 0.466 | 0.462 | 0.394 |

National

Table 9 provides the proportion of all students answering questions correctly in each subdomain or third-level.

Table 9: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year for All Students

| Subdomain/Third-Level | Proportion Correct Expected Graduation Year | | | | Overall |
|--|--|-------|-------|-------|---------|
| | 2028 | 2027 | 2026 | 2025 | |
| 1. Foundational Knowledge for Pharmacy Practice (~25% of Exam) | | | | | |
| A. Pharmaceutical science principles and concepts | - | - | - | - | - |
| 1. Pharmacology (N = 1) | 0.000 | 0.000 | 0.488 | 0.525 | 0.436 |
| 2. Pharmacokinetics, pharmacodynamics, or pharmacogenomics (N = 1) | 0.000 | 0.000 | 0.492 | 0.518 | 0.434 |
| 3. Pharmaceutics (N = 1) | 0.000 | 0.000 | 0.484 | 0.498 | 0.421 |
| B. Pharmaceutical compounding | - | - | - | - | - |
| 1. Nonsterile preparations (N = 2) | 0.000 | 0.232 | 0.508 | 0.497 | 0.453 |
| 2. Sterile preparations (N = 2) | 0.000 | 0.288 | 0.501 | 0.491 | 0.453 |
| C. Pharmaceutical calculations | - | - | - | - | - |
| 1. Patient parameters or laboratory measures (N = 1) | 0.000 | 0.000 | 0.490 | 0.493 | 0.421 |
| 2. Quantities of drugs to be dispensed or administered (N = 3) | 0.167 | 0.352 | 0.499 | 0.505 | 0.473 |
| 3. Rates of administration (N = 1) | 0.000 | 0.000 | 0.532 | 0.510 | 0.444 |
| 4. Dose conversions (N = 1) | 0.000 | 0.000 | 0.471 | 0.498 | 0.417 |
| 5. Drug concentrations, ratio strengths, osmolality, or osmolality (N = 1) | 0.000 | 0.000 | 0.503 | 0.479 | 0.419 |
| 6. Quantities of drugs or ingredients to be compounded (N = 2) | 0.000 | 0.237 | 0.510 | 0.515 | 0.463 |
| 7. Nutritional needs and the content of nutrient sources (N = 1) | 0.000 | 0.000 | 0.491 | 0.494 | 0.422 |
| 8. Biostatistical, epidemiological, or pharmaco-economic measures (N = 1) | 0.000 | 0.000 | 0.493 | 0.517 | 0.434 |

(continued ...)

Table 9: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year for All Students (*continued*)

| Subdomain/Third-Level | 2028 | 2027 | 2026 | 2025 | Overall |
|--|-------|-------|-------|-------|---------|
| 9. Pharmacokinetic parameters (N = 2) | 0.000 | 0.266 | 0.496 | 0.504 | 0.455 |
| D. Drug development processes (eg, clinical trial phases, emergency use authorizations) (N = 1) | 0.000 | 0.000 | 0.501 | 0.493 | 0.425 |
| E. Research design principles and biostatistics (eg, blinding, randomization, biases, statistical tests and outcomes, ethics) (N = 2) | 0.000 | 0.252 | 0.509 | 0.503 | 0.458 |
| F. Retrieval, assessment, and interpretation of primary, secondary, and tertiary resources (N = 2) | 0.000 | 0.257 | 0.497 | 0.505 | 0.455 |
| 2. Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) (~25% of Exam) | | | | | |
| A. Prescriptions and medication order interpretation | - | - | - | - | - |
| 1. Drug names and therapeutic classes (N = 3) | 0.146 | 0.356 | 0.507 | 0.496 | 0.471 |
| 2. Indications, usage, and dosing regimens (N = 1) | 0.000 | 0.000 | 0.485 | 0.525 | 0.435 |
| 3. Available dosage forms (N = 2) | 0.000 | 0.247 | 0.494 | 0.484 | 0.443 |
| 4. Prescription regulations (eg, boxed warnings, risk evaluation and mitigation strategies) (N = 1) | 0.000 | 0.000 | 0.535 | 0.497 | 0.439 |
| 5. Safety and effectiveness (eg, laboratory parameters, vital signs) (N = 3) | 0.169 | 0.314 | 0.492 | 0.495 | 0.462 |
| B. Therapeutic substitutions (eg, formulary restrictions, therapeutic alternatives, shortages, biosimilars) (N = 2) | 0.000 | 0.245 | 0.507 | 0.507 | 0.459 |
| C. Immunization services and documentation | - | - | - | - | - |
| 1. Indications and scheduling (N = 3) | 0.180 | 0.342 | 0.488 | 0.500 | 0.466 |

(continued ...)

Table 9: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year for All Students (*continued*)

| Subdomain/Third-Level | 2028 | 2027 | 2026 | 2025 | Overall |
|--|-------|-------|-------|-------|---------|
| 2. Contraindications and precautions (N = 1) | 0.000 | 0.000 | 0.487 | 0.489 | 0.418 |
| 3. Storage and handling (N = 2) | 0.000 | 0.248 | 0.513 | 0.509 | 0.462 |
| 4. Administration (eg, techniques, preparation, routes) (N = 2) | 0.000 | 0.268 | 0.489 | 0.492 | 0.448 |
| 5. Adverse reactions (N = 3) | 0.172 | 0.351 | 0.518 | 0.497 | 0.476 |
| D. Medication handling, storage, stability, and disposal (eg, hazardous and nonhazardous drugs, controlled substances, parenteral medications, sharps handling, temperature control) (N = 2) | 0.000 | 0.260 | 0.488 | 0.490 | 0.445 |
| 3. Person-Centered Assessment and Treatment Planning (~40% of Exam) | | | | | |
| A. Medication history, allergy history, and reconciliation (N = 3) | 0.156 | 0.323 | 0.484 | 0.500 | 0.462 |
| B. Health histories, screenings, and assessments (N = 1) | 0.000 | 0.000 | 0.474 | 0.487 | 0.412 |
| C. Patient health conditions, including special populations and medication-related factors | - | - | - | - | - |
| 1. Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology (N = 2) | 0.000 | 0.255 | 0.505 | 0.499 | 0.455 |
| 2. Appropriateness of therapy (eg, medications, immunizations, nondrug therapy, dosing, contraindications, warnings, evidencebased decision making) (N = 1) | 0.000 | 0.000 | 0.514 | 0.489 | 0.427 |
| 3. Interactions (eg, drug-drug, drug-condition, drug-food, drugallergy, drug-laboratory) (N = 1) | 0.000 | 0.000 | 0.504 | 0.475 | 0.417 |

(continued ...)

Table 9: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year for All Students (*continued*)

| Subdomain/Third-Level | 2028 | 2027 | 2026 | 2025 | Overall |
|--|-------|-------|-------|-------|---------|
| 4. Errors and omissions (eg, dosing, duplication, additional therapy needed, unnecessary therapy) (N = 3) | 0.180 | 0.339 | 0.506 | 0.494 | 0.469 |
| 5. Adverse drug reactions (N = 3) | 0.185 | 0.344 | 0.498 | 0.514 | 0.477 |
| 6. Toxicologic exposures and overdoses (N = 2) | 0.000 | 0.230 | 0.498 | 0.501 | 0.451 |
| 7. Adherence (N = 3) | 0.198 | 0.350 | 0.523 | 0.514 | 0.487 |
| D. Therapeutic monitoring, plan development, evaluation, and modifications | - | - | - | - | - |
| 1. Therapeutic goals, clinical endpoints, and follow-up (N = 2) | 0.000 | 0.257 | 0.480 | 0.489 | 0.442 |
| 2. Safety (N = 3) | 0.148 | 0.332 | 0.500 | 0.513 | 0.474 |
| 3. Effectiveness (N = 4) | 0.279 | 0.382 | 0.492 | 0.506 | 0.479 |
| E. Patient education | - | - | - | - | - |
| 1. Lifestyle modifications and health maintenance (N = 1) | 0.000 | 0.000 | 0.496 | 0.514 | 0.434 |
| 2. Medication use, storage, and disposal (N = 3) | 0.182 | 0.331 | 0.517 | 0.497 | 0.474 |
| 3. Disease state management (N = 1) | 0.000 | 0.000 | 0.518 | 0.489 | 0.429 |
| F. Over-the-counter medications and dietary supplements (N = 4) | 0.262 | 0.381 | 0.511 | 0.502 | 0.483 |
| G. Devices to administer medications and self-monitoring tests (N = 3) | 0.206 | 0.318 | 0.510 | 0.488 | 0.467 |
| 4. Professional Practice (~5% of Exam) | | | | | |
| A. Adverse drug event reporting and medication error reporting (eg, MedWatch, VAERS) (N = 1) | 0.000 | 0.000 | 0.514 | 0.463 | 0.414 |
| B. Public health initiatives and risk-prevention programs (eg, tobacco and nicotine cessation, antimicrobial stewardship, health screenings, opioid stewardship) (N = 2) | 0.000 | 0.260 | 0.500 | 0.503 | 0.456 |

(continued ...)

Table 9: Average Proportion Correct in Subdomain or Third-Level by Expected Graduation Year for All Students (*continued*)

| Subdomain/Third-Level | 2028 | 2027 | 2026 | 2025 | Overall |
|--|-------|-------|-------|-------|---------|
| C. Social determinants and drivers of health (N = 1) | 0.000 | 0.000 | 0.492 | 0.483 | 0.417 |
| D. Ethical considerations (eg, informed consent, ethical principles, professional conduct and responsibility, patient confidentiality) (N = 1) | 0.000 | 0.000 | 0.513 | 0.489 | 0.427 |
| 5. Pharmacy Management and Leadership (~5% of Exam) | | | | | |
| A. Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety) (N = 1) | 0.000 | 0.000 | 0.508 | 0.512 | 0.437 |
| B. Inventory and supply management (eg, drug recalls, drug shortages) (N = 1) | 0.000 | 0.000 | 0.509 | 0.505 | 0.434 |
| C. Quality improvement activities (eg, medication use evaluation, root-cause analysis, continuous quality improvement) (N = 2) | 0.000 | 0.237 | 0.490 | 0.505 | 0.451 |
| D. Mentorship and preceptorship (eg, providing and receiving feedback, delegation of work activities, preceptor roles) (N = 1) | 0.000 | 0.000 | 0.496 | 0.483 | 0.418 |

This page intentionally left blank.



END OF REPORT